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Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by 
clonal expansion of pleuripotent hematopoetic stem cells. The incidence of CML is 1 to 2 cases 
per 100,000 people per year; in the Western Hemisphere, CML accounts for 15% of leukemias 
in adults. Discovery of the speciﬁ  c karyotypic abnormality of the Philadelphia (Ph) chromosome 
in the pathogenesis of CML has led to a better understanding of the disease and hence to an 
advancement of targeted therapeutics. Availability of imatinib as an accepted targeted therapy 
in newly diagnosed patients has changed the treatment paradigm in CML. The majority of CML 
patients in chronic phase achieve excellent and durable responses with standard-dose imatinib. 
Mechanisms of primary and secondary resistance to imatinib in CML have been extensively 
studied and newer tyrosine kinase inhibitors are now being evaluated for clinical use. It is 
important that at any time the CML treatment and response remain optimal and thus patients on 
imatinib require continuous monitoring for early detection of resistance. This review will discuss 
the treatment and guidelines for monitoring CML patients in the imatinib era.
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Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by 
clonal expansion of pleuripotent hematopoetic stem cells leading to accumulation of 
cells of myeloid lineage in the peripheral blood, bone marrow and extramedullary 
sites. In the chronic phase, the progenitor cells retain their ability to differentiate to 
myeloid lineage cells, but as the disease progresses to accelerated phase and blast 
crisis (AP and BC) differentiation is suppressed. The incidence of CML is 1 to 2 cases 
per 100,000 people per year; in the Western hemisphere, CML accounts for 15% of 
leukemias in adults. For the year 2008 it is estimated that about 4,830 new cases of 
CML will be diagnosed in the United States.1 Discovery of the speciﬁ  c abnormality 
of the karyotype, the Philadelphia (Ph) chromosome2 linked to the pathogenesis of 
CML, has led not only to a better understanding of the disease but to advancement of 
targeted therapeutics and cure.
The Ph chromosome, the result of a t(9;22) reciprocal translocation, is identiﬁ  ed 
in over 90% of patients with chronic myeloid leukemia (CML).3 The translocation 
results in the juxtaposition of DNA sequences from the BCR and ABL genes,4,5 which 
encodes the oncoprotein, p210BCR-ABL. The dysregulated tyrosine kinase activity 
of BCR-ABL as a result of the gene translocation is essential for leukemogenesis in 
CML. Identiﬁ  cation of the BCR-ABL tyrosine kinase, the product of the chimeric gene 
produced by the Ph chromosome as the molecular abnormality in CML, has enabled 
the development of targeted kinase inhibitors which have revolutionized the treatment 
of the disorder.
In the laboratory, infection of murine models with retrovirus encoding P210bcr/abl 
led to the development of CML.6 It was then validated that BCR-ABL alone is sufﬁ  cient OncoTargets and Therapy 2009:2 64
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to cause CML in animal models.7 Further mutational 
analysis has demonstrated that the constitutive activation 
of tyrosine kinase protein is required for oncogenic activity 
and leukemogenesis in CML.6,7 Recognition of the tyrosine 
kinase (TK) activity of the Bcr-Abl proteins led to the 
discovery of a new series of compounds targeted against 
BCR-ABL–encoded proteins, which inhibited the TK 
activity (Figure 1), thus aborting the signals controlling the 
leukemic phenotype. It was hypothesized that an inhibitor 
of the BCR-ABL tyrosine kinase should be an effective 
and selective treatment for CML. To this end, STI571 
(4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-
(3-pyridinyl)-2-pyrimidinyl] amino] phenyl] benzamide 
methanesulfonate (imatinib, Gleevec®; Novartis, Basel, 
Switzerland), a potent and selective inhibitor of the tyrosine 
kinase activity of BCR-ABL,8 was studied in early phase I 
studies in patients with CML in the chronic phase. High 
response rates were observed among those treated with 
daily doses of 300 mg or more and therapy with STI571 was 
also well tolerated. Due to relatively speciﬁ  c biochemical 
activity, high response rates, acceptable pharmacokinetics 
and minimal toxicity proﬁ  le, imatinib was rapidly introduced 
into clinical practice.
Imatinib is a small-molecule drug which inhibits the 
BCR-ABL tyrosine kinase by competitively binding at the 
ATP-binding site and blocking the downstream signaling 
pathways necessary for leukemogenesis.8 Imatinib has now 
become standard treatment for newly diagnosed CML and has 
created a paradigm shift for targeted management of cancer 
in general. This review will discuss the role of imatinib in the 
management of CML, guidelines for monitoring and follow 
up of patients on imatinib, and future challenges associated 
with tyrosine kinase inhibition in CML.
Management of newly diagnosed CML
The majority of patients in the Western Hemisphere are 
diagnosed in the chronic phase of CML. Imatinib mesylate 




















Figure 1 Mechanism of action of imatinib. A)   The phosphorylation and activation of tyrosine residue after binding of adenosine triphosphate ATP in the kinase domain 
on the BCR-ABL oncoprotein. B) Prevention of phosphorylation and activation of tyrosine residue when imatinib binds to the kinase domain. Adapted with permission 
from Savage DG, Antman KH. Imatinib mesylate – a new oral targeted therapy. N Engl J Med. 2002;346:683–693.41 Copyright © 2002 Massuchusetts Medical Society. All 
rights reserved.OncoTargets and Therapy 2009:2 65
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diagnosed patients with CML. More than half of patients with 
late chronic-phase CML after failure of interferon alfa-based 
therapy and over 80% of newly diagnosed patients achieve 
a complete cytogenetic response.9 Based on the IRIS study 
data, in December 2002, the Food and Drug Administration 
(FDA) granted approval for imatinib as frontline treatment 
for patients with CML.
Deﬁ  nition of responses to imatinib
The standardized criteria for responses among patients with 
CML on treatment is as follows.10
Hematologic response
Complete: Deﬁ  ned as platelet count 450 × 109/L; white 
blood cell count 10 × 109/L; differential without immature 
granulocytes and with less than 5% basophils; nonpalpable 
spleen.
Partial: Deﬁ  ned as above except for presence of immature 
cells, platelet count 50% of pretreatment but 450 × 109 L, 
persistent splenomegaly but 50% pretreatment size.
Cytogenetic response
Complete: No Ph+ metaphases
Major: 0% to 35% Ph+ metaphases (complete + partial)
Partial : 1% to 35% Ph+ metaphases
Minor: 35% to 90% Ph+ metaphases
None: Ph+  95%
Molecular response
Complete: bcr-abl mRNA transcript nonquantiﬁ  able and 
nondetectable by RT-PCR.
Major: more than or equal to 3 log reduction of bcr-abl mRNA 
transcript.
Standard dose imatinib
A dose of 300 mg orally (PO) daily was sufﬁ  cient to achieve 
a CHR in almost all chronic phase CML patients, but 
standard dose which is 400 mg daily is well explored and 
appears to be easily tolerated. Doses lower than 400 mg are 
discouraged and cautioned for the possible development of 
resistance.11 The superiority of 400 mg imatinib PO daily 
over recombinant interferon alfa and low-dose cytarabine 
was conﬁ  rmed in a prospective randomized international 
study (International Randomized Study of Interferon and 
STI571 [IRIS]).12 In this phase III clinical trial, 1106 patients 
were randomized to imatinib at a dose of 400 mg daily 
or interferon alfa plus cytarabine. At a follow up around 
60 months, imatinib was superior to recombinant interferon 
alfa for efﬁ  cacy, with a complete hematologic response rate 
of 95% versus 55%, a complete cytogenetic response rate 
of 76% versus 15% and progression-free survival (PFS; 
survival free from progression to AP/BC) at 19 months of 
97% versus 91% (p  0.001). The annual rate of progres-
sion to AP/BC appeared to be fairly constant in the ﬁ  rst 4 
years of treatment: 1.5%, 2.8%, 1.6% and 0.9%; long-term 
follow up is awaited.13 Because of the remarkable remission 
rates with imatinib led to the crossover of most patients in 
the interferon alfa group to the imatinib group, long-term 
comparisons of survival for imatinib and interferon alfa 
are not possible. Analysis of the IRIS study shows that the 
Sokal score, which is based on age, spleen size, platelet 
and peripheral blood blast count,14 is well correlated with 
the likelihood of achieving complete cytogenetic response: 
91% for low-, 84% for intermediate- and 69% for high-
risk patients. But patients who achieved a major molecular 
response at 12 months were also free from progression at 
54 months, and none of these individuals had progressed to 
AP or BC, regardless of pretherapeutic Sokal risk group.9 
Among patients lacking a complete cytogenetic response 
at 12 months, 28% had progressed by 54 months, and 11% 
to AP or BC. These data underscore the need for close 
monitoring for responses periodically once treatment with 
imatinib is initiated.
High-dose imatinib
Patients in accelerated phases of CML who were treated with 
imatinib at 400 or 600 mg/d were evaluated for hematologic 
and cytogenetic response, time to progression, survival and 
toxicity. In comparison with 400 mg, imatinib doses of 
600 mg/d led to more cytogenetic responses (28% compared 
to 16%), longer duration of response (79% compared with 
57% at 12 months), time to disease progression (67% 
compared with 44% at 12 months), and overall survival 
(OS: 78% compared with 65% at 12 months), with no 
clinically relevant increase in toxicity.9,15 Thus, a daily dose 
of 600 mg was likely to be more effective than 400 mg for 
AP/BC patients.
Since at higher concentrations imatinib may inhibit 
more effectively BCR-ABL and some mutants, studies 
were initiated to test higher doses also in chronic phase. 
In patients with both prior hematologic and cytogenetic 
resistance to 400 mg of imatinib daily, increasing the dose 
to 800 mg resulted in a complete hematologic remission 
in 65% of patients and a complete cytogenetic response in 
18% of treated patients.15 Compared with standard-dose 
imatinib, 800 mg daily dose of imatinib was associated OncoTargets and Therapy 2009:2 66
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with signiﬁ  cantly better complete cytogenetic response 
(p = 0.0005), major molecular response (p = 0.00001) and 
complete molecular response (p = 0.001) at the price of 
frequent myelosuppression.16 The role of high-dose imatinib 
(400 mg daily) upfront in chronic phase patients with 
high-risk features is being evaluated in clinical studies and 
remains a category 2A recommendation according to the 
National Comprehensive Cancer Care Network (NCCN) 
guidelines.17 Interim results of TOPS (Tyrosine Kinase 
Inhibitor Optimization and Selectivity), which compared 
400 mg with 800 mg, had shown that high-dose imatinib is 
associated with rapid major molecular responses, but this 
difference was not statistically signiﬁ  cant from that achieved 
with standard-dose imatinib.18
Late chronic phase and imatinib
Patients who were in chronic phase, but resistant or intolerant 
to interferon alfa or who had been treated with conventional 
chemotherapy, are classiﬁ  ed as late chronic phase. At 5 years 
of follow up in phase II trials, 69% of such patients treated 
with imatinib overall were free from progression to AP or 
BC.16,19,20 Long-term follow up (72 months) of late chronic 
phase patients from the Italian Cooperative Study Group 
on CML showed a complete cytogenetic response rate of 
55% and major molecular response rate of 68%.19 Overall 
the survival of cytogenetic responders was more than 90% 
and the PFS and OS of complete cytogenetic responders 
have remained superior after a median observation time of 
6 years. Achievement of a complete cytogenetic response in 
late chronic phase is prognostically as important as in early 
stage chronic phase CML patients and was stable over the 
follow up period.
Clinical results in AP and BC
In the majority of patients with CML in BC and 
Ph-chromosome–positive acute lymphocytic leukemia (ALL), 
the leukemic clone remains at least partially dependent on 
BCR-ABL for survival. BC (Table 1) is highly refractory to 
conventional induction therapy with chemotherapeutic drugs. 
A study conducted by Druker et al showed that imatinib was 
active with an overall response rate in the myeloid blast 
crisis of 55%, and the rate of complete remission was 11%. 
Sustained hematologic response and complete hematologic 
response was noted in 36% and 9% of previously untreated 
patients. Major cytogenetic response (16%) and complete 
cytogenetic response (7%) were markedly higher in patients 
treated with an initial imatinib dose of 600 mg daily than in 
those given 400 mg daily.21 The PFS and median survival of 
patients treated with imatinib in AP and BC were short; thus 
though imatinib remains a useful strategy even in advanced 
phases, these patients will beneﬁ  t from combination therapies 
and stem cell transplantation.15
Response rates or the durability of responses in patients 
with lymphoid BC and those with Ph-chromosome–positive 
ALL were similar in clinical studies. Overall response rate in 
patients with lymphoid BC or Ph-chromosome–positive ALL 
was 70%, and 20% of patients had complete remissions,15 with 
early relapse in most patients.
Adverse effects to imatinib
Adverse events (Table 2) with imatinib are generally 
mild, with rare grade 3 or 4 toxicities. Myelosuppression 
(neutropenia, thrombocytopenia, anemia) is the most 
frequent adverse event (16.7% in the IRIS study). These are 
manageable with supportive therapy with growth factors 
and blood transfusions without the need for interruption 
of imatinib. Mild elevation in liver enzymes (5.3%) and 
peripheral edema (4.5%) were other notable side effects. 
Decreasing ﬂ  uid intake or diuretics are helpful for managing 
ﬂ  uid retention. Other side effects may include gastrointestinal 
intolerance, rash, myalgia, arthralgia and drug interactions 
due to inhibition of the P450 pathway. In smaller series, 
changes in bone and mineral metabolism and congestive 
heart failure were associated with imatinib treatment. 
Table 1 Deﬁ  nition of chronic, accelerated and blastic phases of chronic myeloid leukemia by World Health Organization Criteria
CML phase deﬁ  nition
Chronic phase
Presence in peripheral blood or bone marrow of blasts 10%, basophils 20%, blasts and promyelocytes 30%, and platelets 100 × 109/L
Accelerated phase
Peripheral blood or bone marrow blasts of 10%–19%, or blasts and promyelocytes 30%, or basophils 20%, or platelets 100 × 109/L not related to 
therapy, or chromosomal abnormalities other than the Ph chromosome, or progressive splenomegaly
Blast crisis
Presence of 20% blasts in blood or bone marrow or evidence of extramedullary blast inﬁ  ltration (except liver, spleen, or lymph nodes) or large 
clusters of blasts in bone marrow biopsyOncoTargets and Therapy 2009:2 67
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Little information about possible teratogenicity of imatinib 
in human beings is available; use of contraception during 
imatinib treatment is recommended.
Diagnostic evaluation and disease 
monitoring
At diagnosis, cytogenetics, reverse transcription-polymerase 
chain reaction (RT-PCR), and ﬂ  uorescence in situ hybrid-
ization (FISH) are performed in addition to complete 
blood count, bone marrow biopsy, staging and Sokal risk 
stratification (spleen size and extramedullary disease). 
Recommendations for follow up and monitoring are outlined 
in Table 3.
Bone marrow biopsies should be done at 6-month intervals 
until achievement of complete cytogenetic response, to 
determine disease status. Evaluation of bone marrow samples 
for cytogenetic abnormalities is essential to rule out clonal 
cytogenetic evolution during therapy, which identiﬁ  es patients 
at high risk of relapse. Once complete cytogenetic response 
is achieved, monitoring can continue with quantitative 
RT-PCR (qPCR) from peripheral blood at 3-month intervals. 
Though few patients (around 5% of patients) with cytogenetic 
responses have developed clonal cytogenetic abnormalities 
in Ph-negative cells, the signiﬁ  cance of this ﬁ  nding is less 
clear.22–24 The risk of progression to myelodysplastic syndrome 
or acute myeloid leukemia from such abnormalities in 
Ph-negative cells is rare and thus, outside of a research setting 
and in the absence of signiﬁ  cant hematologic abnormalities 
such as cytopenias, dysplastic morphology or Ph-negative 
clonal cytogenetic abnormalities on preceding biopsies, regular 
bone marrow biopsies may not be indicated. For complete 
cytogenetic responders, quantitative PCR remains the main-
stay of monitoring continued response to imatinib.
Deﬁ  nition of failure of standard-dose 
imatinib
Follow up of the IRIS study at 60 months indicates that 16% 
of patients failed therapy with imatinib and 7% progressed 
to AP or BC. Presence of factors such as derivative chro-
mosome 9 deletion, additional chromosome aberrations in 
Ph-positive cells at diagnosis, less than major molecular 
response at 12 months, or any increase in transcription of 
BCR-ABL or other chromosomal aberrations may suggest 
that standard doses may not be adequate, thus warranting 
more close observation in this subset of patients.25–27 Imatinib 
failure is deﬁ  ned as no hematological response at 3 months, 
incomplete hematological response or no cytogenetic 
response at 6 months, less than partial cytogenetic response 
at 12 months, less than complete cytogenetic response at 
18 months, loss of complete hematological or cytogenetic 
remission, or detection of highly resistant mutations of 
BCR-ABL at any time. Suboptimal response is deﬁ  ned as 
incomplete hematological response at 3 months, less than 
partial cytogenetic response at 6 months, less than com-
plete cytogenetic response at 12 months, less than major 
molecular remission at 18 months, loss of major molecular 
response, mildly resistant mutations, or other chromosome 
abnormalities. It is imperative to follow patient responses 
Table 2 Frequency of adverse effects among patients receiving imatinib for chronic myeloid leukemia
Dose/toxicity Chronic phase (n 532) Accelerated phase (n 235) Blast phase (n 260)
Dose
 400  mg/day








 Nausea 68 71 69
 Edema 56 71 69
 Cramps 50 37 26
 Diarrhea 37 53 41
 Vomiting 30 55 52
 Rash 39 43 34
 Headache 30 29 26
 Fatigue 31 36 28
 Arthralgia 30 29 24
 Neutropenia 34 58 63
 Thrombocytopenia 17 43 60
 Anemia 5 39 51OncoTargets and Therapy 2009:2 68
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closely and recognize suboptimal response or treatment 
failure at the earliest to perform additional tests and make 
necessary adjustments to treatment regimen.
Primary resistance
Failure to achieve a complete hematologic response by 
3 months, cytogenetic response by 6 months, or major 
cytogenetic response by 12 months after starting imatinib 
is referred to as imatinib treatment failure and warrants a 
change in therapy. Primary hematologic resistance is rare 
in chronic phase CML but primary cytogenetic resistance 
is evident in 15% to 25% of patients. Drug transporters 
play an important role in uptake and elimination via 
gastrointestinal tract of imatinib. They also determine 
intracellular drug concentration. Drug efflux proteins 
have been extensively studied, and their overexpression 
has been frequently implicated as a cause of resistance. In 
this regard, high expression of the ATP-binding cassette 
(ABC) transporter is also known to decrease intracellular 
concentration of imatinib.28,29 Similarly low organic cation 
transporter-1 (OCT-1) activity may play a role in decreasing 
intracellular concentration of imatinib and predispose to 
resistance.28,29
Secondary resistance
Relapse or secondary resistance is deﬁ  ned as a loss of 
complete hematologic response, conﬁ  rmed loss of partial 
or complete cytogenetic response, or a confirmed 30% 
increase of Ph-positive metaphases deﬁ  ned relapse. In one 
study, a single 2-fold rise of BCR-ABL transcripts was highly 
predictive of mutations in the kinase domain of BCR-ABL 
and subsequent relapse. For patients treated with BCR-ABL 
kinase inhibitor therapy, it is important to investigate by 
both mutation and cytogenetic analyses the cause of rising 
BCR-ABL levels.
Cytogenetic abnormalities in the Ph-positive clone have 
been detected in 58% of imatinib-resistant patients. The 
detection of a second Ph chromosome indicates ampliﬁ  cation 
of the BCR-ABL gene, which has been reported as a 
mechanism of imatinib resistance with an overall frequency 
of about 18%.25 Rising BCR-ABL levels may be also related 
to inconsistent therapy (poor compliance), which should be 
considered.
Among the mechanisms known for imatinib resistance, 
point mutations are emerging as the major cause of resistance. 
Mutations that involve direct contact points between imatinib 
and Abl may impair binding by steric hindrance. Later disease 
stages, older age, prior interferon therapy, development of 
clonal evolution, high-risk Sokal score at diagnosis, and 
failure to achieve a complete cytogenetic response with 
imatinib may be associated with mutations and resistance to 
imatinib therapy.30 Failure to achieve a complete cytogenetic 
response by 12 months of imatinib therapy was associated 
with the detection of mutations in 28% of patients. Thus, it 
is suggested that kinase domain mutational analysis should 
be performed when there is failure of response to imatinib or 
suboptimal response, and rising BCR-ABL levels.
Association between mutations in the P-loop of the 
BCR-ABL kinase domain and a poorer prognosis for 
patients who were treated with imatinib has been reported in 
some clinical studies31,32 but not in others.33 Kinase domain 
mutations detected at the P-loop and at residues T315 and 
M351 constitute 60% to 85% of all mutations tested. Other 
mechanisms of secondary resistance include activation of Src 
family of kinases and additional chromosomal abnormalities 
in Ph-positive cells
Options for patients with a suboptimal 
response to standard-dose imatinib
Any patient with a suboptimal response or signs of resistance 
should be considered for a clinical trial, primarily with an 
alternative Abl kinase inhibitor or dose escalation of imatinib, 
which will be effective in 30% to 50% of patients.34 However, 
these responses may last for a short time period and stem cell 
transplantation should be considered as an option for patients 
with low transplant risk and failure to achieve complete 
hematologic response.
Approximately 30% of chronic-phase patients who will 
not respond or inevitably relapse can be identiﬁ  ed by close 
monitoring at diagnosis; they can be offered secondary 
tyrosine kinase inhibitors or transplantation at the outset. It 
is now known that Bcr-Abl remains the optimal target even 
Table 3 Monitoring patients on imatinib
Hematologic response Cytogenetic response Molecular response
Recommended monitoring 
interval
Every 2 weeks until complete 
response, then every 3 months 
unless otherwise required
Every 6 months until complete 
response achieved and conﬁ  rmed, 
hence at least every 12 months
Every 3 months; mutational 
analysis in case of failure, suboptimal 
response, or transcript level increaseOncoTargets and Therapy 2009:2 69
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at the time of relapse and has driven the search for alternative 
approaches to restore target inhibition. There is evidence in 
the majority of patients with acquired resistance of either 
increased expression of Bcr-Abl or, more frequently, muta-
tions in the kinase domain of Bcr-Abl that interfere with 
drug binding.
Alternative Abl inhibitors that exhibit increased 
potency have been evaluated in phase I/II trials and have 
demonstrated very encouraging clinical activity. Nilotinib 
is approximately 20-fold more potent than imatinib and 
dasatinib. Initially developed as a Src kinase inhibitor 
but also noted to be an extremely potent inhibitor of Abl 
(300-fold greater activity than imatinib), nilotinib is active 
against most imatinib-resistant kinase Abl mutants, with 
the notable exception of the T315I mutant.35,36 Responses 
in patients in AP were also impressive and appear to be 
mostly stable. Given these excellent results, treatment with 
an alternative Abl kinase inhibitor is probably the best 
drug therapy option available for patients with primary or 
acquired resistance to imatinib.
In summary, the recommendation for patients with 
mutations at Y253, E255 and T315 is allogeneic transplant, 
another kinase inhibitor, or investigational treatments, as 
these suggest high-level imatinib resitance and failure.37 
Others such as mutations at residues M244, F317 and M351 
may respond to an increased imatinib dose, as they indicate 
low level resistance.37 Mutations in addition to the above 
may have clinical signiﬁ  cance, although much more remains 
to be learnt.
Imatinib vs other second-generation 
tyrosine kinase inhibitors
Comparative studies of imatinib and dasatinib or bosutinib 
or combinations of tyrosine kinase inhibitors are ongoing. 
Some of these trials are outlined in Table 4. A recent study 
reported by Kantarjian et al of high dose imatinib (800 mg) 
vs dasatinib 70 mg for patients who had failed to respond 
to standard dose imatinib showed that the responses were 
comparable between two groups, suggesting that increasing 
the dose of imatinib is still a reasonable option.38
Clonal cytogenetic abnormalities 
on imatinib
Ph-chromosome–negative hematopoiesis consists of cells 
derived from nonleukemic hematopoietic stem cells. Studies 
have described clonal cytogenetic abnormalities in Ph-nega-
tive cells from some patients who had a cytogenetic response 
to imatinib. In various studies, the frequency of such patients 
ranged from 2% to 15%.23,24 Some patients with typical 
chromosomal abnormalities had developed acute myeloid 
leukemia or myelodysplastic syndromes others have done 
well.23 Due to the fact that the available data are limited, the 
overall prognosis for such patients is unknown.
Role of allogeneic transplantion 
in imatinib era
Stem cell transplantation is the only treatment modality with 
the potential for cure in CML. While long-term data are still 
not available, because the likelihood of disease progression 
to AP or BC during the ﬁ  rst year of imatinib therapy is only 
1.5% and the transplant-related mortality during the ﬁ  rst 
12 months is 10% to 20%, imatinib therapy is warranted as 
ﬁ  rst choice in all patients.
NCCN recommends evaluation for stem cell transplantation 
for all patients who do not achieve a cytogenetic response 
at 6 months following imatinib therapy or have cytogenetic 
relapse at 12 or 18 months after achieving initial hematologic 
remission, achieve partial cytogenetic response at 18 months, 
and who have T3151 mutation and have failed on imatinib, 
dasatinib or nalotinib.
In contrast to its use in the chronic phase, there is a well-
deﬁ  ned role for stem cell transplantation in the management 
Table 4 Active imatinib/combination phase III randomized studies
Study site randomization
Germany/Switzerland Imatinib ± interferon alfa or cytarabine vs interferon followed by stem cell transplant
France Imatinib 400 mg vs imatinib 400 mg + cytarabine vs imatinib 400 mg + peginterferon alfa-2a vs imatinib 600 mg
Austria Imatinib 800 mg followed by imatinib 400 mg compared with a continuous treatment with imatinib 400 mg
Israel Imatinib vs imatinib and peginterferon after complete cytogenetic response with imatinib therapy
USA/UK Nilotinib 300 mg vs 400 mg twice daily vs imatinib 400 mg
Multinational Dasatinib vs imatinib
Multinational Bosutinib vs imatinibOncoTargets and Therapy 2009:2 70
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of advanced CML, when imatinib responses tend to be 
transient and short lived. Thus, in patients who progressed 
to AP/BC on imatinib, the novel Abl kinase inhibitors will 
likely induce transient remission and serve as a bridge to stem 
cell transplantation.
Imatinib combinations
A multicentric, phase II study of imatinib 400 mg daily 
and pegylated interferon alfa in the treatment of 76 early 
chronic phase Ph-positive CML patients confirmed the 
excellent response to front-line imatinib and the stability of 
the complete cytogenetic response. Any possible additional 
beneﬁ  t of the combination with interferon alfa remained 
uncertain due to poor compliance to interferon.
The efﬁ  cacy of the triple combination regimen with 
interferon alfa, ara-C, HHT and sequential imatinib therapy 
were evaluated in newly diagnosed Ph-positive CML, which 
resulted in improved estimated 5-year survival rates.
More combinations with imatinib have been studied but 
randomized clinical trials are ongoing around the world, some 
of which are outlined in Table 4.
Summary
Availability of imatinib as an accepted targeted therapy 
in newly diagnosed patients has changed the treatment 
paradigm in CML. Yet identiﬁ  cation of newer mechanisms of 
resistance to imatinib and various molecular mutations have 
made overall management of CML complex. The majority 
of CML patients in chronic phase achieve excellent and 
durable responses with standard-dose imatinib, but since 
resistance can develop at any time during treatment, close 
monitoring, including quantitative PCR, is crucial. Newer 
Abl kinase inhibitors, such as nilotinib and dasatinib, with 
activity against mutant Bcr-Abl, are the most promising drug 
therapy for imatinib failure in chronic phase. Eligible patients 
with AP or BC should undergo allogeneic transplant, with 
imatinib or alternative tyrosine kinase inhibitor therapies used 
for bridging, as responses are short lived (3 months or so). 
Pre-treatment with imatinib does not seem to affect transplant 
outcome at any phase.39
Future research
Currently, we are unable to identify up-front a small subgroup 
of high-risk patients who will not respond well to tyrosine 
kinase inhibition (primary resistance). Systematic screening 
for kinase domain mutations on patients before imatinib or 
to predict response or secondary resistance to imatinib is not 
recommended as it may not be cost-effective. Higher doses 
of imatinib or combination of tyrosine kinase inhinitors in 
chronic phase are not clear awaiting clinical trial results, and 
whether earlier achievement of these responses is important 
for progression-free survival remains largely unknown. It 
has not been resolved whether patients with undetectable 
BCR-ABL will be able to cease imatinib treatment and 
maintain response. A recent report indicates that this may 
be the case for selected patients, at least in the short term.40 
Additional mutations that may play a role in mediating 
secondary resistance to imatinib are not yet known and are 
being studied. In short, development of imatinib has led to 
better understanding of CML as a disease that has in turn led 
to development of more potent targeted therapies such as the 
second- and third-generation tyrosine kinase imhibitors to 
overcome resistance and further improve clinical outcome.
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